Dr. Reddy’s Laboratories has announced the approval of new employee stock option grants by its Nomination, Governance and Compensation Committee. The board has sanctioned a total of 1,192,234 options across two primary schemes. These grants are set to vest 100% at the end of a 3-year period, with an exercise price of Rs. 1,293.90 per share, reflecting the company’s commitment to incentivizing its workforce and aligning long-term performance with employee growth.
Breakdown of Stock Option Grants
On May 11, 2026, the company’s committee authorized the distribution of equity-based incentives to eligible staff members. The grants are divided into two categories under distinct incentive programs:
- Indian Stock Options: A total of 816,119 options granted under the 2018 employee scheme.
- ADR Stock Options: A total of 376,115 options granted under the 2007 American Depository Receipt scheme.
Terms and Vesting Schedule
Both sets of options have been issued with an identical exercise price of Rs. 1,293.90 per share. The vesting structure for these awards is standardized, requiring a 3-year tenure before 100% of the options become available for exercise. This long-term vesting schedule ensures that employees remain invested in the sustained value creation and operational success of the organization over the coming years.
Strategic Alignment
These grants, administered by the company’s oversight committee, serve as a key component of the company’s compensation strategy. By aligning employee interests with the performance of company shares, Dr. Reddy’s aims to foster a culture of ownership and high performance among its eligible staff base globally.
Source: BSE
